Standout Papers

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease 2017 2026 2020 2023 386
  1. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease (2017)
    Vicente E. Torres, Arlene B. Chapman et al. New England Journal of Medicine

Immediate Impact

54 standout
Sub-graph 1 of 22

Citing Papers

The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation
2024 Standout
Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
2024 Standout
2 intermediate papers

Works of Olga Sergeyeva being referenced

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
2017 Standout
Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.
2008

Author Peers

Author Last Decade Papers Cites
Olga Sergeyeva 308 389 146 251 16 712
Lukas Foggensteiner 150 376 154 401 18 798
Bunyong Phakdeekitcharoen 162 340 121 327 33 697
Yiyi Ma 121 277 53 187 21 748
Marvin Grieff 355 96 181 147 19 761
Kyoko Nagasue 450 140 117 73 11 607
Michiel J.S. Oosterveld 274 36 105 204 37 728
T.-Christian H. Mix 329 44 64 85 10 581
Lavinia Negrea 475 166 310 168 20 786
G Krishnamurthy 267 109 42 320 13 693
Wai Cheung 370 33 97 126 18 831

All Works

Loading papers...

Rankless by CCL
2026